{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002285","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.460037+00:00","generated_at":"2026-06-27T03:32:36.321279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q4 2021 revenue $17.1M, cash $716.6M; FT596 data shows 69% ORR, FT516 gets RMAT","bullets":["Q4 2021 revenue $17.1M from collaborations; R&D expenses $69.5M (incl. $9.4M stock comp).","Cash position $716.6M at Dec 31, 2021; FY2022 GAAP loss from ops guided $335-365M; cash use $290-315M; year-end cash >$400M.","FT596+R single-dose cohorts (≥90M cells, n=16): 69% ORR, 56% CR; no ICANS or GVHD.","FDA granted RMAT designation for FT516 in r/r DLBCL; expansion cohorts enrolling at 900M cells/dose.","Initial FT819 dose cohort cleared with no DLTs; Janssen collaboration triggered milestone for second CAR NK candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002285","json":"https://secwatch.observer/filing/0000950170-22-002285.json","markdown":"https://secwatch.observer/filing/0000950170-22-002285.md","text":"https://secwatch.observer/filing/0000950170-22-002285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022002285/0000950170-22-002285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022002285/fate-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:32:36.321279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}